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Abstract To determine risk factors for additional non-
sentinel lymph node metastases in neck dissection speci-
mens of patients with early stage oral cancer and a positive
sentinel lymph node biopsy (SLNB). A retrospective
analysis of 36 previously untreated SLNB positive patients
in our institution and investigation of currently available
literature of positive SLNB patients in early stage oral
cancer was done. Degree of metastatic involvement [clas-
sified as isolated tumor cells (ITC), micro- and
macrometastasis] of the sentinel lymph node (SLN), the
status of other SLNs, and additional non-SLN metastases in
neck dissection specimens were analyzed. Of 27 studies,
comprising 511 patients with positive SLNs, the pooled
prevalence of non-SLN metastasis in patients with positive
SLNs was 31 %. Non-SLN metastases were detected
(available from 9 studies) in 13, 20, and 40 % of patients
with ITC, micro-, and macrometastasis in the SLN,
respectively. The probability of non-SLN metastasis seems
to be higher in the case of more than one positive SLN (29
vs. 24 %), the absence of negative SLNs (40 vs. 19 %), and
a positive SLN ratio of more than 50 % (38 vs. 19 %).
Additional non-SLN metastases were found in 31 % of
neck dissections following positive SLNB. The presence of
multiple positive SLNs, the absence of negative SLNs, and
a positive SLN ratio of more than 50 % may be predictive
factors for non-SLN metastases. Classification of SLNs
into ITC, micro-, and macrometastasis in the future SLNB
studies is important to answer the question if treatment of
the neck is always needed after positive SLNB.
Keywords Sentinel lymph node biopsy  Mouth
neoplasms  Neck dissection  Lymph nodes  Lymphatic
metastasis  Neoplasm micrometastasis
Introduction
Sentinel lymph node biopsy (SLNB) has been introduced
for the detection of occult lymph node metastasis in
patients with early stage oral cancer. Observational trials
(with only neck dissection after positive SLNB) have
demonstrated that SLNB is a sensitive method in the
detection of occult cervical lymph node metastases. A
recent meta-analysis found a pooled sensitivity of 91 %
(95 % CI 84–95 %) and a negative predictive value rang-
ing from 92 to 98 % when follow-up was used as reference
standard [1]. Long-term follow-up studies showed that
SLNB is a safe procedure [2, 3]. Recently, we reported a
sensitivity of 93 % and a negative predictive value of 97 %
of SLNB in our first 90 early oral cancer patients [4].
Metastatic tumor deposits can be categorized as isolated
tumor cells (ITC), micrometastasis, and macrometastasis.
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ITCs are generally defined as tumor deposits B0.2 mm
(pN0i?), micro- (pN1mi), and macrometastases (pN1) as
tumor deposits of 0.21–2.0 mm and[2.0 mm, respec-
tively. In addition, for ITC, more specific histopathological
characteristics have been described: no contact with vessel
or lymph sinus wall, no extravasation, no extravascular
stromal reaction, and no extravascular tumor cell prolifer-
ation [5].
So far, the same strategy has been used in the case of
sentinel nodes with ITCs, micro-, and macrometastases,
which means a (selective) neck dissection. Broglie et al.
found significantly higher hazard ratios in overall disease
specific and disease free survival for micrometastases and
macrometastases, whereas ITCs were significant determi-
nants for disease specific survival compared with SLN
negative patients [6].
A report of a European multicenter study on 109 oral
squamous cell carcinoma patients with positive SLNB
showed additional (non-SLN) metastases in 34.4 % of the
neck dissection specimens [7].
The recent update of this trial demonstrated a statistically
lower overall survival for micro- and macrometastases
compared with ITC [8]. If a reliable nomogram to predict
non-SLN metastases based on degree of metastatic tumor
deposits in SLNs can be developed, SLNB might be a
therapeutic rather than just a diagnostic procedure, i.e.,
avoiding subsequent tumor-negative neck dissections. The
aim of the present retrospective study and the literature
review is to analyze risk factors for the presence of non-SLN
metastases in SLNB positive early oral cancer patients.
Materials and methods
Retrospective study
From February 2007 until October 2014, 139 consecutive
patients with cT1-2N0 squamous cell carcinomas of the
oral cavity or oropharynx underwent transoral excision and
SLNB. After approval of the Institutional Review Board
and Ethics Committee, informed consent was obtained
until SLNB was performed as standard procedure in our
institution. SLNB was performed according to the EANM/
SENT joint practice guidelines [9]. A detailed description
of the procedure in our institution had been described
previously [4].
A positive SLNB was followed by (selective) neck
dissection in 36/37 (97 %) patients (one patient with ITC
was treated by radiotherapy only, which was indicated for
adverse histopathological findings of the primary tumor).
The neck dissection specimen was histopathologically
examined for additional lymph node metastases using a
routine procedure (no step-serial sectioning and
immunohistochemistry). The presence and localization
(level) of additional lymph node metastasis were scored for
each patient.
The numbers of tumor positive (1 vs.[1) and negative
(0 vs. C1) SLNs and their ratio (B50 vs.[50 %) were
scored for each patient.
Literature analysis
Studies included in recent meta-analyses [1, 10] were
analyzed for data on the degree of metastatic involvement
of SLN, the status of other SLNs, and additional non-SLN
metastases in neck dissection specimens following positive
SLNB. In addition, references were explored to identify
other relevant articles. If presented (or could be subtracted
from the data provided), the rate of positive non-SLN was
scored for ITC, micrometastasis, macrometastasis, number
of positive SLNs (1 vs.[1), number of negative SLNs (0
vs. C1), and their ratio ratio (B50 vs.[50 %) per patient.




At least one histopathologically positive SLN was found in
36/139 (26 %) of patients, yielding a total of 43 positive
SLNs. One patient with a paramedian T1 tongue tumor was
diagnosed with bilateral positive SLNs. In both neck sides,
the largest tumor deposit in the positive SLN, respectively,
ITC, and macrometastasis, was separately investigated.
The remaining patients with at least two positive SLNs had
only unilateral metastasis, and the largest tumor deposit
was taken for evaluation and follow-up of the neck.
Overall, we analyzed 36 patients with 37 SLN positive
neck sides, subdivided into 7 necks with ITC, 14 with
micro-, and 16 with macrometastasis (Tables 1, 2).
In none of the SLNs with ITC based on size, extrava-
sation, extravascular stromal reaction or extravascular
tumor cell proliferation were found, but all these SLNs had
contact with lymph sinus wall.
In 6/36 (17 %) patients who underwent a subsequent
neck dissection, additional lymph node metastases were
found. All patients had T2 tumors and the SLN had con-
tained a macrometastasis (Table 3).
Additional non-SLN metastases were found in level I
(n = 3), level III (n = 6), level IV (n = 1), and level V
(n = 1). In one patient, non-SLN metastasis was restricted
to the same level as the positive SLN, in one patient in
adjacent and non-adjacent levels, and in 4 patients, non-
SLN metastasis were only found in non-adjacent levels.
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If[1 SLN was positive, 2/5 (40 %) of the patients had
additional neck metastases compared to 4/31 (13 %) in
patients with a single positive SLN. In 2/13 (15 %) patients
with solely positive SLN(s), additional non-SLN metas-
tases were found (vs. 17 % if synchronous presence of
negative SLNs was present). If more positive than negative
SLNs were present ([50 % SLN positive), additional non-
SLN metastases were found in 3/14 (21 %) patients com-
pared to 3/22 (14 %) if a similar or higher number of
negative than positive SLNs were found (Table 3).
Review of the literature
Eleven studies [6, 11–20] had categorized the size of tumor
deposits in SLNs. Including the data from our study, ITC
was present in 17 % of 234 patients (range 0–37 %),
micrometastasis in 41 % (19–100 %), and macrometastasis
in 43 % (0–76 %) (Table 3). Additional non-SLN metas-
tases were mainly found in levels I, II, and III and some-
times in level IV or V [7, 13, 15, 16, 21, 22]. The pooled
prevalence of non-SLN metastasis in patients with positive
SLN(s) of this study and 26 other studies
[6, 7, 11–17, 21–37] was 31 % (156/511).
The pooled probability of non-SLN metastasis in this
present study and 8 other studies [6, 11, 13, 15–17, 23, 25]was
13 % (4/32), 20 % (11/55), and 40 % (19/49) for ITC,micro-,
and macrometastases, respectively. This probability was
26 % (37/144) for micro- and macrometastases combined.
Including our results, a higher pooled prevalence for
additional non-SLN metastases had been found when[1
positive SLNs were present (29 vs. 24 %)
[11, 13, 16, 22–24, 30], the absence of negative SLNs (40
vs. 19 %) [13, 15, 16, 22–24, 30, 33, 37], and in the case of
a positive SLN ratio of more than 50 % (38 vs. 19 %)
[13, 16, 22–24, 30, 33]. Results are shown in Table 3.
Table 1 Data of demographic
and tumor-related patient
characteristics
Characteristic Overall (%) Status of SLNB
Negative (%) Positive (%)
Patients, n (%) 139 (100 %) 103 (74 %) 36 (26 %)
Gender, n (%)
Male 71 (51 %) 54 (52 %) 17 (47 %)
Female 68 (49 %) 49 (48 %) 19 (53 %)
Median age (year) (range) 60 (27–86) 60 (27–85) 62 (29–86)
Tumor location, n (%)
Tongue 86 (61 %) 62 (60 %) 24 (66 %)
Floor of mouth 40 (29 %) 31 (30 %) 9 (25 %)
Buccal mucosa 6 (4 %) 6 (6 %) 0
Inferior alveolar process 4 (3 %) 2 (2 %) 2 (6 %)
Soft palate 3 (2 %) 2 (2 %) 1 (3 %)
Clinical T stage, n (%)
T1 97 (70 %) 81 (79 %) 16 (44 %)
T2 42 (30 %) 22 (21 %) 20 (56 %)
No of SLNs 328 285 (87 %) 43 (13 %)
Follow-up, (m) (range)
Observation time (months) 36 (1–102) 36 (1–102) 36 (1–98)
SLNB sentinel lymph node biopsy, SLNs sentinel lymph nodes
Table 2 Prevalence of ITC, micrometastasis, and macrometastasis in
positive SLNs
Study All ITC Micro Macro
Barzan [11] 2a 0 (0 %) 1 (50 %) 1 (50 %)
Mozillo [12] 4 0 (0 %) 4 (100 %) 0 (0 %)
Stoeckli [13] 9 1 (11 %) 5 (56 %) 3 (33 %)
Keski-Sa¨ntti [14] 2 0 (0 %) 1 (50 %) 1 (50 %)
Bilde [15] 11 3 (27 %) 6 (55 %) 2 (18 %)
Atula [16] 34 5 (15 %) 14 (41 %) 15 (44 %)
Kovacs [17] 9 0 (0 %) 3 (33 %) 6 (67 %)
Alkureishi [18] 42b 0 (0 %) 10 (24 %) 32 (76 %)
Burcia [19] 38 14 (37 %) 15 (39 %) 9 (24 %)
Terada [20] 5 0 (0 %) 3 (60 %) 2 (40 %)
Broglie [6] 42 10 (24 %) 19 (45 %) 13 (31 %)
Present study 36 6 (16 %) 14 (39 %) 16 (44 %)
Total 234 39 (17 %) 95 (41 %) 100 (43 %)
ITC isolated tumor cells; micro micrometastasis; macro
macrometastasis; SLN sentinel lymph node
a Only results of cNO early oral cancer
b Definition of micrometastasis: only detected by step-serial sec-
tioning and/or immunohistochemistry
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Discussion
Patients with positive SLNB undergo generally subsequent
(completion) neck dissection, because there is no reliable
means of detecting or predicting non-SLN metastasis.
SLNB is associated with significant less morbidity than
elective neck dissection and identification of patients who
do not benefit from subsequent neck dissection may
decrease this morbidity even further [38].
The prediction of the presence of non-SLN metastasis in
the neck after positive SLNB can theoretically be improved
in two ways: dividing the tumor deposits in SLNs into sub-
groups or adding other predictive factors in a risk profile.
Combining this study with our analysis of the literature,
we found an inverse relation between the size of tumor
deposits in the SLN and the probability of a non-SLN:
13 % for ITC, 20 % for micrometastasis, and 40 % for
macrometastasis. Since the prevalence of non-SLN
metastasis in the neck dissection specimen following ITC
in SLNs is substantial, in early stage oral cancer, one
cannot refrain from neck dissection after any category of
positive SLNB. When patients with a low risk of non-SLN
metastasis can be identified, a wait and scan policy using
USgFNAC may be justified [39].
The commonly used definition of isolated tumor cells is
based on size (0.2 mm or less) rather than designation of
the metastatic tumor deposit. ITC is then considered to be a
small micrometastasis ‘‘waiting to grow’’ (precursor of
micrometastasis) with a risk these necks with SLNs con-
taining ITC may also harbor micro- or macrometastases
[40]. In this study, all ITCs based on size had the same
morphologic features: no extravasation, extravascular
stromal reaction or extravascular tumor cell proliferation,
but all had contact with lymph sinus wall. Since these
deposits seem to be real ITC, this latter feature is
debatable.
Review of the literature revealed that only a limited
number of small studies classified SLN tumor deposits in
ITC, micrometastasis, and macrometastasis. The wide
variety of rates of the different categories in our literature
review may reflect the lack of uniformly used definitions.
Consequently, these numbers are too low to perform
reliable statistical analyses on the risk of non-SLN metas-
tases in these different tumor deposits in SLNs. To explore
if patients with ITC or micrometastasis in SLNs need a
subsequent neck dissection, it is important that all future
studies report SLN metastases in these categories. Only,
then, the question if SLNB can be used as treatment, and
not only as diagnostic procedure, in patients selected by the
type of tumor deposit in SLNs can be answered.
In breast cancer, SLNB is accepted as standard diag-
nostic technique for clinically node negative patients.
Complete axillary lymph node dissection is generally rec-
ommended if the SLNB is positive. Non-SLN metastases
are detected in 35–50 % of SLN positive patients. Only
some series report that the prevalence of ITC and distinc-
tion between ITC and micrometastasis could be difficult
[41, 42]. The reported rate of micrometastasis as the largest
tumor deposit in SLN positive breast cancer patients varies
considerably: from 24 to 93 % [43]. In patients with tumor
deposits in SLNs, the prevalences of ITC, micrometastasis,
and macrometastasis are 7–16, 16–32, and 58–78 %,
respectively. Non-SLN metastases are found in 0–13,
12–27, and 48–50 % in patients with ITC, micro-, and
macrometastases in SLNs, respectively [44–49].
Different nomograms in predicting non-SLN metastases
in breast cancer patients with a positive SLNB have been
developed, usually including the largest detected size of
SLN metastasis and the proportion of involved SLNs
among all removed SLNs [43]. The treatment strategy for
micrometastasis in SLN is under debate. It has been sug-
gested to refrain patients with ITC in their SLN from
axillary lymph node dissection [44–46]. A recent review
including 7151 breast cancer patients with positive SLNB
in whom an axillary lymph node dissection was omitted
revealed an axillary recurrence rate of 0.7 % (range
0–7.1 %) for macrometastasis and 0.3 % (range 0–3.4 %)
for micrometastasis and ITC. Unfortunately, micrometas-
tasis and ITC could not be analyzed separately, and details
regarding adjuvant treatment were lacking in the majority
of studies [50]. Since breast cancer patients are often
treated with adjuvant systemic therapy, these strategies
cannot easily be translated to early oral cancer patients who
are usually treated with surgery as monotherapy.
A meta-analysis of predictive factors for non-SLN
metastases in breast cancer patients with a positive SLN
confirmed a high likelihood of non-SLN metastases for size
of SLN metastasis of more than 2 mm [macrometastasis;
odds ratio (OR) 4.22], extracapsular extension in the SLN
(OR 4.10), one or less negative SLN (OR 2.66), more than
one positive SLN (OR 2.60), tumor size[2 cm (OR 2.41),
a ratio of positive SLN of more than 50 % (OR 2.25), and
lymphovascular invasion (OR 2.24) [51]. Recently, the
same authors developed a risk score based on these
parameters [52].
In oral oncology, Gurney et al. [7] reported other pre-
dictive factors for the presence of non-SLN metastases in
SLNB positive necks: tumor site (higher risk as the primary
tumor was located at the posterior part of the oral cavity),
increased stage (T2–4 stage at higher risk), and number of
negative SLNs (lower risk in higher number of negative
SLNs). In this study, all patients with non-SLN metastases
had T2 oral squamous cell carcinoma. Although tumor
thickness or depth of invasion [53] and molecular markers
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[54] has predictive value for the presence of (occult) lymph
node metastasis, their role in predicting the presence of
non-SLN metastasis in oral cancer patients with a positive
SLNB is not known yet.
Our retrospective study suggests if both a positive SLN
and a negative SLN are present the prevalence of non-SLN
metastases seems nearly equal compared to patients with
solely positive SLNs, in contrast to other studies (Table 3).
Since distinguishing real SLNs from the second echelon
nodes may be difficult [55], it can be anticipated that (some
of) these negative SLNs may be, in fact, the second echelon
nodes. If more positive than negative SLNs are present, the
probability of non-SLN metastases seems to be higher, also
in case of a ratio of positive SLNs of more than 50 %. Due
to the low number of cases, statistical analysis could not be
performed and more larger studies are needed to confirm
these ideas.
A large multicenter study showed in 1/122 neck dis-
sections following positive SLNBs of early oral cancer
non-SLN metastases in levels other than I–III [7]. These
non-SLN metastases had been found in 15 % of the
patients in the same level, in 17 % in an adjacent level, and
in 2 % in a non-adjacent level. In our retrospective study,
all non-SLN metastases were found in levels I–IV except
one in level V. In this latter patient, two positive SLNs and
five additional non-SLNs were found. In 67 % (4/6) of the
patients, non-SLNs were only found in non-adjacent levels.
If the future studies report on the level involved by non-
SLN metastases, more tailored (super)selective neck dis-
sections may be defined.
Analysis of the literature, including our present study,
showed that additional non-SLN metastases were found in
31 % of neck dissections following positive SLNB.
Selected by tumor deposit, these percentages were 13 %
for ITC, 20 % for micro-, and 40 % for macrometastasis in
SLNs. This prevalence may be underestimated, since, in
most studies, non-SLNs are examined using routine
histopathological examination without step-serial section-
ing and immunohistochemistry. Studies on neck dissection
specimens show that immunohistochemistry can reveal
small metastases in 15 % of the patients that remain
undetected in routine H&E staining [56].
Reporting other risk factors may be useful to develop
a nomogram selecting SLNB positive patients for neck
dissection and active surveillance or wait and scan fol-
low-up. The presence of more than one positive SLN,
the absence of negative SLNs (besides a positive SLN),
and a positive SLN ratio of more than 50 % may be
predictive factors for non-SLN metastasis in SLNB
positive patients. To this point, there is no well-argued
reason to refrain from an additional neck dissection
based on these risk factors or tumor size in the SLN.
The presented data support the use of a selective neck
dissection, when because of an SLNB positive neck an
additional neck dissection is indicated.
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